Banque Pictet & Cie SA Purchases 142,543 Shares of Gilead Sciences, Inc. $GILD

Banque Pictet & Cie SA raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 168.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 227,007 shares of the biopharmaceutical company’s stock after acquiring an additional 142,543 shares during the quarter. Banque Pictet & Cie SA’s holdings in Gilead Sciences were worth $27,863,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Linden Thomas Advisory Services LLC grew its holdings in Gilead Sciences by 2.6% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 49,553 shares of the biopharmaceutical company’s stock worth $6,082,000 after purchasing an additional 1,279 shares during the period. Bank Pictet & Cie Europe AG raised its stake in Gilead Sciences by 893.5% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 151,893 shares of the biopharmaceutical company’s stock valued at $18,643,000 after acquiring an additional 136,605 shares during the period. Weatherly Asset Management L. P. bought a new stake in Gilead Sciences in the 4th quarter valued at $207,000. RHS Financial LLC lifted its holdings in Gilead Sciences by 4.8% during the 4th quarter. RHS Financial LLC now owns 4,482 shares of the biopharmaceutical company’s stock valued at $550,000 after purchasing an additional 205 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in Gilead Sciences by 7.6% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 84,484 shares of the biopharmaceutical company’s stock valued at $10,370,000 after purchasing an additional 5,990 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.7%

Shares of GILD opened at $140.30 on Thursday. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29. The company has a market cap of $174.14 billion, a P/E ratio of 20.72, a P/E/G ratio of 1.83 and a beta of 0.37. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The firm has a 50 day simple moving average of $144.85 and a two-hundred day simple moving average of $129.14.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter last year, the business posted $1.90 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is currently 48.45%.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the chief financial officer owned 179,191 shares in the company, valued at $25,844,717.93. The trade was a 1.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares in the company, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 299,280 shares of company stock worth $42,820,550. Insiders own 0.27% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Ouro Medicines and struck a binding collaboration with Galapagos to advance T‑cell engager programs for autoimmune diseases — a clear push to expand its pipeline into potentially high‑value biologics and diversify beyond core antiviral franchises, which supports longer‑term growth expectations. Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
• Positive Sentiment: RBC noted decent patient persistence for Yeztugo (HIV prevention), indicating commercial uptake is intact even if market expansion is limited — positive for ongoing revenue stability from Gilead’s HIV portfolio. Gilead Sciences Shows Solid Early Yeztugo Persistence but Limited Market Expansion, RBC Says
• Neutral Sentiment: Analysts expect single‑digit EPS growth for Q1 2026 — modest growth that keeps expectations muted vs. high‑growth peers but aligns with Gilead’s guidance and stable cash generation. This sets tempered near‑term performance expectations. Gilead Sciences’s Q1 2026 Earnings: What to Expect
• Neutral Sentiment: Market roundups and earnings/transcript coverage show Gilead’s stock has risen in recent sessions but still lagged broader indices — reflecting investor caution despite positive headlines. These pieces mainly summarize momentum rather than introduce new catalysts. Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
• Neutral Sentiment: General investor commentary listing Gilead as an attractive dividend/ income name may support demand from income investors but is not an immediate catalyst for a large re‑rating. Markets Haven’t Changed. These 2 Cheap Dividends Still Rule
• Negative Sentiment: Gilead extended the tender offer for Arcellx at $115 plus a $5 CVR — the extension signals the deal hasn’t closed and increases short‑term uncertainty (and potential near‑term cash outflow). Investors may view extensions as a risk that the acquisition will be more costly, contested, or delayed. Gilead Extends Tender Offer to Acquire Arcellx

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research reports. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Argus increased their target price on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Jefferies Financial Group started coverage on Gilead Sciences in a report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price target for the company. UBS Group lifted their target price on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Wolfe Research upped their price target on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.